FINWIRES · TerminalLIVE
FINWIRES

Utz Brands' Underlying Growth Remains Strong, RBC Capital Markets Says

作者

-- Utz Brands' (UTZ) quarter-to-date trends appear soft but underlying growth remains solid, driven by distribution gains, innovation, and California expansion momentum, RBC Capital Markets said in a note Thursday.

Management is optimistic that the company's new products will support topline growth and that the company is well-covered for most of the year on fuel, agricultural commodities, and freight, easing inflationary concerns, according to the note.

Full-year guidance for the salty snacks category still assumes an approximately flat growth, which analysts said is appropriate given the noisy Q1 and consumer environment.

Following the roughly in-line Q1 results and reaffirmed guidance, the brokerage said it is adjusting its 2026 estimates to reflect organic sales growth of 2.5%, EBITDA growth of 6%, and an EPS decline of 4.1%.

RBC Capital Markets maintained its outperform rating on the stock, with a price target of $15.

Shares of Utz Brands were down 5% in Thursday trading.

Price: $7.88, Change: $-0.42, Percent Change: -5.06%

相关文章

Sectors

行业动态:消费类股午后小幅走低

周四下午晚些时候,消费类股票小幅下跌,道富消费必需品精选行业SPDR ETF (XLP) 和道富非必需消费品精选行业SPDR ETF (XLY) 均下跌0.1%。 公司新闻方面,Tapestry (TPR) 在公布第三季度业绩超出预期后,上调了2026财年业绩预期,但对其旗下Kate Spade品牌第四季度的销售预期较为保守。受此影响,该公司股价下跌超过13%。 Shake Shack (SHAK) 股价暴跌28%,此前该公司公布的第一季度业绩不及华尔街预期。 Planet Fitness (PLNT) 股价暴跌32%,此前该公司因第一季度新增会员数量低于预期而下调了全年业绩预期。 麦当劳 (MCD) 公布的第一季度业绩好于预期,尽管该公司称其面临“充满挑战”的市场环境,但同店销售额的反弹幅度仍超过市场预期。其股价上涨了0.3%。

$MCD$PLNT$SHAK$TPR
Sectors

板块动态:医疗保健股午后走软

周四下午晚些时候,医疗保健类股下跌,纽约证券交易所医疗保健指数下跌0.6%,道富医疗保健精选行业SPDR ETF (XLV)下跌0.7%。 iShares生物技术ETF (IBB)下跌2.2%。 公司新闻方面,据路透社周四报道,Entrada Therapeutics (TRDA) 的股价暴跌57%,此前该公司用于治疗杜氏肌营养不良症儿童的药物在早期至中期临床试验中未达到分析师预期。 Iovance Biotherapeutics (IOVA) 的股价下跌超过13%,此前该公司第一季度亏损收窄幅度小于预期,且营收不及预期。 Harmony Biosciences (HRMY) 的股价下跌5.5%,此前该公司第一季度盈利和营收均低于分析师预期。 Catalyst Pharmaceuticals (CPRX) 股价上涨 2.1%,此前该公司同意被 Angelini Pharma 以约 41 亿美元的股权价值收购。该公司还表示,已与 Hetero Labs 达成和解协议,以解决有关 Firdapse 拟推出的仿制药版本的专利诉讼。

$CPRX$HRMY$IOVA$TRDA
Research

——国家银行将Cascades的目标股价从14加元下调至13加元,维持该板块“与大盘持平”的评级,并指出第一季度业绩与下调后的预期一致,第二季度预期疲软,之后将出现复苏,资产出售工作将在第三季度完成。国家银行表示,第一季度业绩预计与下调后的预期相符,第二季度预期疲软,之后将出现复苏,资产出售工作将在第三季度完成。

Price: $10.72, Change: $-0.23, Percent Change: -2.10%

$CAS.TO